Following this session, the attendee will be able to:

- Identify and diagnose pyoderma gangrenosum
- Design an evaluation schema for a patient with pyoderma gangrenosum
- Manage patients with pyoderma gangrenosum more effectively

Jeffrey P. Callen, MD
Professor of Medicine (Dermatology)
University of Louisville

Dermatologic Clinic at Gottschalk Medical Plaza
1 Medical Plaza Dr, Irvine, CA (Second Floor)
8 to 8:45 a.m.—Patient Viewing
Neilsen Library
125 Med Surg I
8:45 to 10 a.m.—Patient Discussion
10:15 to 11:15 a.m.—Lecture

Activities approved for AMA PRA Category 2 Credits™

And

Dowling Club
Neilsen Library
125 Med Surg I
5 to 7 p.m.

Moderator: Janellien Smith, MD, Professor, Department of Dermatology
UC Irvine Health School of Medicine

Special thanks to Amgen and La Roche Posay for exhibiting at this session.

Wednesday, February 26, 2014
Pyoderma Gangrenosum

The target audience for the Department of Dermatology Grand Rounds is attending physicians, fellows, community physicians and other health care professionals.

Statement of Purpose: The format will include lectures detailing diagnosis, management and therapeutic interventions for selected dermatologic topics, and occasional case presentations with review of interesting cases. Clinical test results and radiographic findings will also be included. Current landmark research findings will be discussed.

Accreditation statement: The University of California, Irvine School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Dermatologic Grand Rounds Global Objectives

- Summarize core competencies in Dermatology as identified by the Accreditation Council for Graduated Medical Education.
- Assessment and management of complex skin diseases including but not limited to cancer.
- Cite current research findings in the field of dermatology and dermatopathology.
- Discuss key issues in the delivery of dermatologic care to a wide range of therapeutic modalities and combination therapy to increase efficacy and minimize side effect profiles.

Designation statement: The University of California, Irvine School of Medicine designates this live activity for a maximum of 3.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure: Lecturer/Moderator: Dr. Callen and Dr. Smith have disclosed that they have no affiliations, arrangements or financial agreements that could be a potential conflict of interest in their presentations. Dr. Callen has further disclosed that this lecture will include discussion of unlabeled, unapproved drugs or devices for pyoderma gangrenosum. Dr. Callen has disclosed that based on this potential conflict of interest he will submit his presentation for review prior to the activity. He further discloses that he will support his presentation and clinical recommendations with the “best available evidence” from medical literature.

Course Director/Planners: Ho He Grande Sarpa, MD, Janellien Smith, MD, and Christopher B. Zachary, FRCP, have disclosed that, as course directors and planners they have no affiliations, arrangements or financial agreements, which could be perceived as a potential conflict of interest. Dr. Callen, MD, has disclosed that, as a course planner, she receives research grant support from Graceway Pharmaceuticals and Candela Corporation, and that she provides research support for Light Sciences Oncology and Nitto Denko, which could be perceived as a potential conflict of interest. Dr. Callen, MD, has disclosed that based on her potential conflict of interest, to the best of her ability, she will ensure that any speakers or content she suggests are free from commercial bias. She will also excuse herself from planning activity content in which she has a conflict of interest. Dr. Callen, MD, has also disclosed that, as an administrative staff, she has no affiliations, arrangements or financial agreements which could be perceived as a potential conflict of interest.

ADA Statement: In compliance with the Americans with Disabilities Act, contact us three days in advance about special needs for any attendee. Contact Judy Hobert at jhobert@uci.edu. In compliance with the Americans with Disabilities Act, contact us three days in advance about special needs for any attendee. Contact Judy Hobert at jhobert@uci.edu or 949-824-4405. This activity is in compliance with California Assembly Bill 1195 which requires continuing medical education activities with patient care components to include curriculum in the subjects of cultural and linguistic competency. For specific information regarding Bill 1195 and definitions of cultural and linguistic competency, please visit the CME web site at www.cme.uci.edu.